Compare Firy Inc. (FIRY) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Neurocrine Biosciences Inc — how do they compare? Firy Inc. trades at $10.21 (market cap $163.57M), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 102.5× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| FIRY | NBIX | |
|---|---|---|
Market Cap | $163.57M | $16.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $185.50 |
52-Week Low | $2.28 | $123.10 |
Enterprise Value | $107.24M | $16.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY stock trades at $10.45, up 4.5% today, with a bullish technical signal from moving averages. The company shows improving revenue trends ($104.5M in 2025, projected to $112M in 2026) but continues to post significant losses (-$70.4M net income). Recent developments include a successful $719M legal victory and corporate rebranding from Skillz Inc. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings.
While technical indicators suggest near-term upside potential, fundamental challenges persist with negative profitability metrics and cash burn. The stock presents speculative appeal based on legal wins and revenue stabilization, but requires careful risk management given ongoing losses and negative cash flow trends.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
